Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q412685> ?p ?o }
Showing triples 1 to 42 of
42
with 100 triples per page.
- Q412685 subject Q6809004.
- Q412685 subject Q7145095.
- Q412685 subject Q9052781.
- Q412685 abstract "Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells. In the United States, it was approved under an accelerated-approval process by the FDA in 2000 for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML); or those who are not considered candidates for standard chemotherapy.Within the first year after approval, the FDA required a black box warning be added to Gemtuzumab packaging. The drug was noted to increase the risk of veno-occlusive disease in the absence of bone marrow transplantation. Later the onset of VOD was shown to occur at increased frequency in Gemtuzumab patients even following bone marrow transplantation. The drug was discussed in a 2008 JAMA article, which criticized the inadequacy of postmarketing surveillance of biologic agents.Common side effects of administration included shivering, fever, nausea and vomiting. Serious side effects included severe myelosuppression (suppressed activity of bone marrow, which is involved in formation of various blood cells [found in 98% of patients]), disorder of the respiratory system, tumor lysis syndrome, Type III hypersensitivity, venous occlusion, and death.".
- Q412685 atcPrefix "L01".
- Q412685 atcSuffix "XC05".
- Q412685 casNumber "220578-59-6".
- Q412685 drugbank "DB00056".
- Q412685 wikiPageWikiLink Q1060890.
- Q412685 wikiPageWikiLink Q1128050.
- Q412685 wikiPageWikiLink Q186889.
- Q412685 wikiPageWikiLink Q211709.
- Q412685 wikiPageWikiLink Q264118.
- Q412685 wikiPageWikiLink Q3799041.
- Q412685 wikiPageWikiLink Q38933.
- Q412685 wikiPageWikiLink Q409744.
- Q412685 wikiPageWikiLink Q422248.
- Q412685 wikiPageWikiLink Q4774572.
- Q412685 wikiPageWikiLink Q48196.
- Q412685 wikiPageWikiLink Q5009814.
- Q412685 wikiPageWikiLink Q546523.
- Q412685 wikiPageWikiLink Q5731687.
- Q412685 wikiPageWikiLink Q5898315.
- Q412685 wikiPageWikiLink Q640448.
- Q412685 wikiPageWikiLink Q6809004.
- Q412685 wikiPageWikiLink Q7145095.
- Q412685 wikiPageWikiLink Q7891.
- Q412685 wikiPageWikiLink Q864868.
- Q412685 wikiPageWikiLink Q901932.
- Q412685 wikiPageWikiLink Q9052781.
- Q412685 wikiPageWikiLink Q998803.
- Q412685 atcPrefix "L01".
- Q412685 atcSuffix "XC05".
- Q412685 casNumber "220578".
- Q412685 drugbank "DB00056".
- Q412685 type ChemicalSubstance.
- Q412685 type Drug.
- Q412685 type ChemicalObject.
- Q412685 type Thing.
- Q412685 type Q8386.
- Q412685 comment "Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myelogenous leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins.".
- Q412685 label "Gemtuzumab ozogamicin".